Pharmacological Actions of Indoxyl Sulfate and AST-120 That Should Be Recognized for the Strategic Treatment of Patients with Chronic Kidney Disease

References

• Pasternack A, Kuhlbaeck B, Tallgren LG. Serum indican in renal disease. Acta Med Scand. 1964;176:751–756. doi:10.1111/j.0954-6820.1964.tb00683.x14259914
   PubMedGoogle Scholar
• Brummer P, Kasanenk A. Serum indican and urinary indican excretion in achlorhydria. Acta Med Scand. 1955;152:123–128. doi:10.1111/j.0954-6820.1955.tb03469.x13258163
   PubMedGoogle Scholar
• Houssay BA. Phenolemia and indoxylemia: their origin, significance, and regulation. Am J Med Sci. 1936;192:615–626. doi:10.1097/00000441-193611000-00004
   Google Scholar
• Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem. 1992;38:1429–1436. doi:10.1093/clinchem/38.8.14291643710
   PubMed Web of Science ®Google Scholar
• Lesaffer G, De Smet R, Lameire N, et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant. 2000;15:50–57. doi:10.1093/ndt/15.1.50
   PubMed Web of Science ®Google Scholar
• Niwa T. Removal of protein-bound uraemic toxins by haemodialysis. Blood Purif. 2013;35(Suppl 2):20–25. doi:10.1159/00035084323676831
   PubMed Web of Science ®Google Scholar
• Sirich TL, Aronov PA, Plummer NS, et al. Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int. 2013;84:585–590. doi:10.1038/ki.2013.15423636170
   PubMed Web of Science ®Google Scholar
• Nigam SK, Wu W, Bush KT, et al. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol. 2015;10:2039–2049. doi:10.2215/CJN.0244031426490509
   PubMed Web of Science ®Google Scholar
• Wu W, Bush KT, Nigam SK. Key role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes. Sci Rep. 2017;7:4939.28694431
   PubMed Web of Science ®Google Scholar
• Mutsaers HA, van den Heuvel LP, Ringens LH, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One. 2011;6:e18438. doi:10.1371/journal.pone.001843821483698
   PubMed Web of Science ®Google Scholar
• Krieter DH, Hackl A, Rodriguez A, et al. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant. 2010;25:212–218. doi:10.1093/ndt/gfp43719755476
   PubMed Web of Science ®Google Scholar
• Meert N, Waterloos M-A, Van Landschoot M, et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs. 2010;34:580–585. doi:10.1111/j.1525-1594.2010.01005.x20545662
   PubMed Web of Science ®Google Scholar
• Meyer TW, Peattie JWT, Miller JD, et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol. 2007;18:868–874. doi:10.1681/ASN.200608086317251385
   PubMed Web of Science ®Google Scholar
• Camacho O, Rosales MC, Shafi T, et al. Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate. Nephrol Dial Transplant. 2016;31:1335–1341. doi:10.1093/ndt/gfw10027190347
   PubMed Web of Science ®Google Scholar
• Poesen R, Mutsaers HAM, Windey K, et al. The influence of dietary protein intake on mammalian tryptophan and phenolic metabolites. PLoS One. 2015;10:e0140820. doi:10.1371/journal.pone.014082026469515
   PubMed Web of Science ®Google Scholar
• Marzocco S, Dal Piaz F, Di Micco L, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif. 2013;35:196–201. doi:10.1159/00034662823485887
   PubMed Web of Science ®Google Scholar
• Niwa T, Emoto Y, Maeda K, et al. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant. 1991;6:105–109. doi:10.1093/ndt/6.2.1051906999
   PubMed Web of Science ®Google Scholar
• Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis. 2006;47:565–577. doi:10.1053/j.ajkd.2005.12.03616564934
   PubMed Web of Science ®Google Scholar
• Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol. 1994;14:207–212.7977482
   PubMed Web of Science ®Google Scholar
• Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002;13:1711–1720. doi:10.1097/01.ASN.0000022017.96399.B212089366
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Ise M, Seo H, et al. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl. 1997;62:S15–22.9350672
   PubMed Web of Science ®Google Scholar
• Bolati D, Shimizu H, Higashiyama Y, et al. Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol. 2011;34:318–323. doi:10.1159/00033085221849772
   PubMed Web of Science ®Google Scholar
• Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004;65:442–451.14717914
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69:1780–1785. doi:10.1038/sj.ki.500034016612331
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Zuo Y, Ma J, et al. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrol Dial Transplant. 2011;26:2491–2497. doi:10.1093/ndt/gfq75921245127
   PubMed Web of Science ®Google Scholar
• Shimazu S, Hirashiki A, Okumura T, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J. 2013;77:390–396. doi:10.1253/circj.CJ-12-071523100090
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:1551–1558. doi:10.2215/CJN.0398060919696217
   PubMed Web of Science ®Google Scholar
• Lin CJ, Wu CJ, Pan CF, et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3693–3700. doi:10.1093/ndt/gfq25120466687
   PubMed Web of Science ®Google Scholar
• Shafi T, Meyer TW, Hostetter TH, et al. Free levels of selected organic solutes and cardiovascular morbidity and mortality in hemodialysis patients: results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) investigators. PLoS One. 2015;10:e0126048. doi:10.1371/journal.pone.012604825938230
   PubMed Web of Science ®Google Scholar
• Cao X-S, Chen J, Zou J-Z, et al. Association of indoxyl sulfate with heart failure among patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10:111–119. doi:10.2215/CJN.0473051425332316
   PubMed Web of Science ®Google Scholar
• Koshikawa S, Koide K, Yamane Y, et al. The effect of AST-120 on delaying initiation of dialysis therapy in end-stage renal disease. Kidney Dial. 1992;32:783–794.
   Google Scholar
• Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kid Dis. 2009;54:459–467. doi:10.1053/j.ajkd.2009.05.01119615804
   PubMed Web of Science ®Google Scholar
• Schulman G, Berl T, Beck GJ, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26:1732–1746. doi:10.1681/ASN.201401004225349205
   PubMed Web of Science ®Google Scholar
• Cha RH, Kang SW, Park CW, et al. A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11:559–567. doi:10.2215/CJN.1201121426912554
   PubMed Web of Science ®Google Scholar
• Cha R-H, Kang SW, Park CW, et al. Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res Clin Pract. 2017;36:68–78. doi:10.23876/j.krcp.2017.36.1.6828392999
   PubMed Web of Science ®Google Scholar
• Schulman G, Berl T, Beck GJ, et al. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. Clin Exp Nephrol. 2018;22:299–308. doi:10.1007/s10157-017-1447-028741050
   PubMed Web of Science ®Google Scholar
• Schulman G, Berl T, Beck GJ, et al. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrol. 2016;17(1):141.27716149
   PubMed Web of Science ®Google Scholar
• Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the national kidney foundation and the US food and drug administration. Am J Kidney Dis. 2014;64:821–835. doi:10.1053/j.ajkd.2014.07.03025441437
   PubMed Web of Science ®Google Scholar